Our Team


  • Patrick Coyle
    Investment Director & Co-Founder

    Founded BioPacificVentures with Andrew Kelly & Bill Kermode in 2005. Experienced venture capital and investment professional. Extensive investment and M&A experience with Big 4 accounting and transaction background. Worked for past 10 years in commercialisation of food, health and FMCG businesses

    Current & previous Board roles include: New Zealand Pharmaceuticals, Vital Foods, CMP Therapeutics, Rissington Breedline, Novotech and EnCoate

    Previous roles: Investment Director, AgResearch; Manager, KPMG Corporate Finance; Manager, Arthur Anderson Corporate Recovery

    Qualifications: BA in Accounting & Financial Management, Member ICAEW

  • Bill Kermode
    Chairman of Investment Committee & Co-Founder

    Founding Director of Direct Capital with two partners & Founder of BioPacificVentures with Andrew Kelly & Patrick Coyle. Deeply experienced professional investor and fund manager.

    Current & previous roles include: Founding Director, Direct Capital; Treasury Trading Manager, Bank of New Zealand; Director Totalisator Agency Board (TAB); Member of the Public Trust Investment Board

    Current & previous Board roles include: NZ Pharmaceuticals, PFOlsen, Transaction Services Limited, Fishpond, EziBuy, Ryman Healthcare, PC Direct, Climate Coatings, Wool Equities

    Qualifications: BSc (Hons), MA (Oxon

  • Andrew Frankham
    Finance Manager

    Extensively experienced finance professional covering management and reporting on corporates of all complexions

    Current & previous roles include: Chartered accounting NZ; Investment Banking UK; Group Finance Manager, Zeus Capital; Finance Director, Direct Capital; Councillor, New Zealand Venture Capital & Private Equity Association

    Qualifications: BComm

  • Direct Capital
    founding firm and co-owner of BioPacificVentures

    New Zealand’s largest private equity and venture capital firm established in 1994

    Remains owned by three of its founding directors, Ross George, Mark Hutton and Bill Kermode

    Has successfully raised more than $800 million across seven funds for investment into private companies in New Zealand and Australia and has a long-term net rate of return to investors (IRR) of over 20% per annum